BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 23915741)

  • 1. Endocrine therapy for advanced/metastatic breast cancer.
    Schiavon G; Smith IE
    Hematol Oncol Clin North Am; 2013 Aug; 27(4):715-36, viii. PubMed ID: 23915741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.
    Robertson JF; Howell A; Gorbunova VA; Watanabe T; Pienkowski T; Lichinitser MR
    Breast Cancer Res Treat; 2005 Jul; 92(2):169-74. PubMed ID: 15986127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.
    Cheung KL; Owers R; Robertson JF
    Endocr Relat Cancer; 2006 Mar; 13(1):251-5. PubMed ID: 16601292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine therapy for early breast cancer.
    Hussain SA; Williams S; Stevens A; Rea DW
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New approaches to reverse resistance to hormonal therapy in human breast cancer.
    Weinberg OK; Marquez-Garban DC; Pietras RJ
    Drug Resist Updat; 2005 Aug; 8(4):219-33. PubMed ID: 16054421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer adjuvant endocrine therapy.
    Cigler T; Goss PE
    Cancer J; 2007; 13(3):148-55. PubMed ID: 17620763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary endocrine therapy as an approach for patients with localized breast cancer deemed not to be surgical candidates.
    Hilton J; Arnaout A; Clemons M
    Curr Opin Support Palliat Care; 2014 Mar; 8(1):53-8. PubMed ID: 24299966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adjuvant treatment of breast cancer. Endocrine therapy].
    Mouridsen HT; Andersen J
    Ugeskr Laeger; 2007 Sep; 169(37):3072-6. PubMed ID: 17877951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women.
    Cardoso F; Bischoff J; Brain E; Zotano ÁG; Lück HJ; Tjan-Heijnen VC; Tanner M; Aapro M
    Cancer Treat Rev; 2013 Aug; 39(5):457-65. PubMed ID: 22840697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant endocrine therapy in breast cancer.
    Abrial C; Mouret-Reynier MA; Curé H; Feillel V; Leheurteur M; Lemery S; Le Bouëdec G; Durando X; Dauplat J; Chollet P
    Breast; 2006 Feb; 15(1):9-19. PubMed ID: 16230013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant endocrine treatment of early breast cancer.
    Lønning PE
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):223-38. PubMed ID: 17512446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal therapy for postmenopausal breast cancer: the science of sequencing.
    Miller WR; Bartlett JM; Canney P; Verrill M
    Breast Cancer Res Treat; 2007 Jun; 103(2):149-60. PubMed ID: 17039263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant endocrine therapies for postmenopausal women with early breast cancer: standards and not.
    Dellapasqua S; Castiglione-Gertsch M
    Breast; 2005 Dec; 14(6):555-63. PubMed ID: 16188442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ
    Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine therapy for the treatment of postmenopausal women with breast cancer.
    Harichand-Herdt S; Zelnak A; O'Regan R
    Expert Rev Anticancer Ther; 2009 Feb; 9(2):187-98. PubMed ID: 19192957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer.
    Iwase H; Yamamoto Y
    Int J Clin Oncol; 2015 Apr; 20(2):253-61. PubMed ID: 25673474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors.
    Fentiman IS
    Int J Clin Pract; 2006 Jun; 60(6):689-93. PubMed ID: 16805754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
    Prat A; Baselga J
    Nat Clin Pract Oncol; 2008 Sep; 5(9):531-42. PubMed ID: 18607391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer.
    Ohno S
    Clin Breast Cancer; 2016 Aug; 16(4):238-46. PubMed ID: 27151773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.